KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...
Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
A widely-used chemotherapy drug used in cancer treatments could greatly increase patients’ long-term risk of hearing loss, according to a study by researchers at Indiana University and the University ...
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India This was a multicenter retrospective cohort study conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results